Hos kvinder uden prævalent rygsøjlefraktur ved baseline var forekomsten af nye radiografisk verificerede rygsøjlefrakturer signifikant reduceret fra 7, 4% for placebo til 4, 4% for Fablyn (relativ reduktion af risiko = 41%, p = 0, 0002).
In women without any prevalent vertebral fractures at baseline, the incidence of new radiographic vertebral fractures was significantly reduced from 7.4% for placebo to 4.4% for FABLYN (relative risk reduction = 41%, p = 0.0002).